Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2026
Italfarmaco announces Health Canada acceptance and priority review of new drug submission for givinostat as a Duchenne muscular dystrophy treatment
10 June 2026 - New drug submission is based on Italfarmaco’s Phase 3 EPIDYS trial data demonstrating meaningful treatment benefits ...
Posted by Michael Wonder on 07 Jul 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
25 June 2026 - Eli Lilly today announced additional details regarding the Medicare GLP-1 Bridge program taking effect 1 July 2026. ...
Posted by Michael Wonder on 06 Jul 2026
New Zealand Pharmaceutical Schedule - 1 July 2026
1 July 2026 - The July 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 06 Jul 2026
More people to access cholesterol lowering medicine
30 June 2026 - PHARMAC will widen access to rosuvastatin, a medicine used to treat high cholesterol and reduce the ...
Posted by Michael Wonder on 06 Jul 2026
PHARMAC funds another ADHD medicine to improve supply
24 June 2026 - PHARMAC will fund another brand of methylphenidate to help improve supply and provide more treatment options ...
Posted by Michael Wonder on 06 Jul 2026
New treatment option recommended for recurrent or metastatic cervical cancer
24 June 2026 - A new treatment option is now available on the NHS for cervical cancer that has come back ...
Posted by Michael Wonder on 06 Jul 2026
First disease-modifying therapy to delay the onset of type 1 diabetes recommended for NHS use
23 June 2026 - A first of its kind therapy that can delay the onset of type 1 diabetes for up ...
Posted by Michael Wonder on 06 Jul 2026
Ascelia Pharma provides update on the Orviglance NDA
3 July 2026 - Ascelia Pharma today announced that it has received a complete response letter from the US FDA regarding ...
Posted by Michael Wonder on 03 Jul 2026
Wegovy, RSV vaccines among drugs on slow track in New Zealand
2 July 2026 - Small countries in a big world can choose to be nimble or they can choose to ...
Posted by Michael Wonder on 03 Jul 2026
Selective PPARα modulator “K-808” (pemafibrate) granted breakthrough therapy designation by the US FDA as a treatment for primary biliary cholangitis
30 June 2026 - Kowa today announced that on 11 June 2026, it received breakthrough therapy designation from the US FDA ...
Posted by Michael Wonder on 03 Jul 2026
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
30 June 2026 - Today, the FDA approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell and ...
Posted by Michael Wonder on 02 Jul 2026
Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
2 July 2026 - Novartis today announced that the European Commission has approved Itvisma (onasemnogene abeparvovec) for the treatment of ...
Posted by Michael Wonder on 02 Jul 2026
‘Lifesaver’ opioid disorder treatment pulled from Australia
1 July 2026 - Sublocade, used to treat people with opioid use disorder, will be removed from the PBS and all ...
Posted by Michael Wonder on 02 Jul 2026
Cogent Biosciences announces submission of new drug application for bezuclastinib in advanced systemic mastocytosis
30 June 2026 - Cogent Biosciences today announced it has submitted its new drug application to the US FDA for ...
Posted by Michael Wonder on 02 Jul 2026
Stoush over ‘archaic pricing’ threatens access to key drugs
1 July 2026 - Thousands of patients with multiple sclerosis face the prospect of losing publicly funded access to vital ...
Posted by Michael Wonder on 02 Jul 2026
Galderma provides progress update regarding relabotulinumtoxinA regulatory submission in the US
1 July 2026 - Galderma today provided progress updates regarding the regulatory review of its pending biologics license application for relabotulinumtoxinA ...